These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study. Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896 [TBL] [Abstract][Full Text] [Related]
4. What predicts the change from episodic to chronic migraine? Bigal ME; Lipton RB Curr Opin Neurol; 2009 Jun; 22(3):269-76. PubMed ID: 19381087 [TBL] [Abstract][Full Text] [Related]
5. Medication overuse and chronic migraine: a critical review according to clinical pharmacology. Ferrari A; Baraldi C; Sternieri E Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1127-44. PubMed ID: 26027878 [TBL] [Abstract][Full Text] [Related]
6. Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine Tracker. Dodick DW; Tepper SJ; Lipton RB; Buse DC; Stewart WF; Bayliss M; Desai P; Sapra S; Anderson K; McInerney-Prichard E Headache; 2018 Oct; 58(9):1358-1372. PubMed ID: 30362524 [TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
8. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Bigal ME; Serrano D; Buse D; Scher A; Stewart WF; Lipton RB Headache; 2008 Sep; 48(8):1157-68. PubMed ID: 18808500 [TBL] [Abstract][Full Text] [Related]
9. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100 [TBL] [Abstract][Full Text] [Related]
10. Botulinum toxins for the prevention of migraine in adults. Herd CP; Tomlinson CL; Rick C; Scotton WJ; Edwards J; Ives N; Clarke CE; Sinclair A Cochrane Database Syst Rev; 2018 Jun; 6(6):CD011616. PubMed ID: 29939406 [TBL] [Abstract][Full Text] [Related]
11. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Lipton RB; Silberstein SD Headache; 2015 Mar; 55 Suppl 2():103-22; quiz 123-6. PubMed ID: 25662743 [TBL] [Abstract][Full Text] [Related]
12. Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application. Diener HC; Donoghue S; Gaul C; Holle-Lee D; Jöckel KH; Mian A; Schröder B; Kühl T Trials; 2022 May; 23(1):382. PubMed ID: 35546412 [TBL] [Abstract][Full Text] [Related]
13. Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy (MOTS) trial. Shao SC; Hentz J; Shank P; Leonard M; Dodick DW; Schwedt TJ Headache; 2024 Jun; 64(6):632-642. PubMed ID: 38780360 [TBL] [Abstract][Full Text] [Related]
14. SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study. Cady R; O'Carroll P; Dexter K; Freitag F; Shade CL Headache; 2014 Jan; 54(1):67-79. PubMed ID: 24021029 [TBL] [Abstract][Full Text] [Related]
15. Patient-Centered Treatment of Chronic Migraine With Medication Overuse: A Prospective, Randomized, Pragmatic Clinical Trial. Schwedt TJ; Hentz JG; Sahai-Srivastava S; Murinova N; Spare NM; Treppendahl C; Martin VT; Birlea M; Digre K; Watson D; Leonard M; Robert T; Dodick DW; Neurology; 2022 Apr; 98(14):e1409-e1421. PubMed ID: 35169011 [TBL] [Abstract][Full Text] [Related]
16. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML Headache; 2013; 53(10):1548-63. PubMed ID: 23992516 [TBL] [Abstract][Full Text] [Related]
17. The role of avoiding known triggers, embracing protectors, and adhering to healthy lifestyle recommendations in migraine prophylaxis: Insights from a prospective cohort of 1125 people with episodic migraine. Casanova A; Vives-Mestres M; Donoghue S; Mian A; Wöber C Headache; 2023 Jan; 63(1):51-61. PubMed ID: 36651502 [TBL] [Abstract][Full Text] [Related]
18. Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. Starling AJ; Hoffman-Snyder C; Halker RB; Wellik KE; Vargas BB; Dodick DW; Demaerschalk BM; Wingerchuk DM Neurologist; 2011 Sep; 17(5):297-9. PubMed ID: 21881477 [TBL] [Abstract][Full Text] [Related]
19. Improving the classification of migraine subtypes: an empirical approach based on factor mixture models in the American Migraine Prevalence and Prevention (AMPP) Study. Lipton RB; Serrano D; Pavlovic JM; Manack AN; Reed ML; Turkel CC; Buse DC Headache; 2014 May; 54(5):830-49. PubMed ID: 24527745 [TBL] [Abstract][Full Text] [Related]